Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

FRIMLEY, England, December 8 /PRNewswire/ --

- Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1)

- At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1)

- Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1)

- Novartis Plans to File for Use in Newly Diagnosed Patients With Ph+ CML in the EU in 2010

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.(1)

In the first head-to-head study of these two oral treatments as initial therapy for this life-threatening leukaemia, nilotinib demonstrated statistically significant improvement over imatinib in key measures of effectiveness used in the trial.(1) These new data were presented as a late breaker abstract at the 51st annual meeting of the American Society of Haematology (ASH), held 5-8 December 2009, in New Orleans, USA.(1)

CML accounts for more than one in six leukaemias in adults, with around 600 new cases being registered in England and Wales each year.(2) The estimated prevalence of CML in 2003 in England and Wales was 2,660 patients.(2)

The trial showed that at 12 months, significantly fewer patients on nilotinib 300mg twice-daily progressed from the initial chronic phase of the disease to the later accelerated or blast crisis phases than those on imatinib 400mg once-daily.(1) This demonstrates that nilotinib provided significantly better control of the disease compared to imatinib.

Nilotinib was generally well tolerated in the study.(1) A small number of patients discontinued due to adverse events.(1)

"The impressive rates of response observed in this study, combined with the very low rate of disease progression seen in nilotinib-treated patients are very encouraging," said Professor Richard Clark, Consultant Haematologist at Royal Liverpool University Hospital and a trialist involved in this study. "Continued improvement in the treatment of Ph+ CML is very important and these results indicate that nilotinib may provide long-term improvement in progression-free survival."

95% of patients with CML have an abnormality known as the Philadelphia chromosome. This chromosome produces a type of protein called Bcr-Abl, which is responsible for the overproduction of the cancerous white blood cells that are the main feature in Ph+ CML.(3) Nilotinib is a potent and selective inhibitor of the Bcr-Abl protein, thereby inhibiting the production of these cancerous cells.(4,5)

"Novartis has been at the forefront of research on the molecular origin of Ph+ CML and this has led to the development of treatments with unprecedented effectiveness and safety," said Panos Alexakos, Oncology Business Unit Head for Novartis UK. "These data are exciting and the deeper molecular response demonstrated provides hope for further improvement in outcomes for patients with Ph+ CML in the future."

Novartis plans to file worldwide applications for approval of nilotinib as a treatment for adult patients with newly diagnosed Ph+ CML. Nilotinib is currently approved in more than 80 countries including the European Union (EU), United States and other countries for the treatment of adult patients with Ph+ CML in chronic phase or accelerated phase who are resistant or intolerant to prior treatment including imatinib.

Notes to editors

Study details

The clinical trial, Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients (ENESTnd), is a Phase III randomised, open-label, multicentre trial comparing the efficacy and safety of nilotinib versus imatinib in adult patients with newly diagnosed Ph+ CML in the chronic phase.(1) It is the largest global randomised comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients.

ENESTnd is being conducted at 220 global sites, including five sites in the UK, in total 846 patients are enrolled. Patients were randomised to receive nilotinib 400mg twice-daily (n = 281), nilotinib 300mg twice-daily (n = 282) or imatinib 400mg once-daily (n = 283).(1) The primary endpoint was MMR at 12 months; a secondary endpoint was CCyR by 12 months. It is planned that patients are followed up for five years. Patients on the imatinib treatment arm who had suboptimal response or treatment failure will be able to escalate dose and/or switch to nilotinib via a protocol extension.

One of the key effectiveness measures used in the study was called major molecular response (MMR). This is defined as the reduction in levels of the Bcr-Abl protein to less than or equal to 0.1% of the level seen before treatment. MMR is an important measure in CML, as data show that patients who achieve MMR are unlikely to progress to the later stages of the disease.(6) With nilotinib 300mg twice-daily, the rate of MMR at 12 months was twice that of patients receiving imatinib 400mg once-daily (44% vs. 22%, p < 0.0001).(1)

Another effectiveness measure used in the study was called complete cytogenetic response (CCyR). CCyR indicates that no CML cells containing the Ph chromosome can be seen in a sample of bone marrow taken from the patient. 80% of patients achieved CCyR with nilotinib versus 65% with imatinib 400mg once-daily (p < 0.0001).(1) Responses were achieved faster in the nilotinib group than in the imatinib group.(1)

All patients had a minimum of 12 months of treatment or discontinued early; the median follow-up was 14 months. Overall, 84%, 82% and 79% of patients remained in the study on nilotinib 300mg twice-daily, nilotinib 400mg twice-daily and imatinib 400mg once-daily, respectively.(1)

About Ph+ CML

CML is a disease in which the body produces cancerous (leukaemic) white blood cells. 95% of patients with CML have an abnormality known as the Philadelphia chromosome. This chromosome produces a protein called Bcr-Abl, which is responsible for the proliferation of leukaemic white blood cells in Ph+ CML.(3)

CML accounts for more than one in six leukaemias in adults, with around 600 new cases being registered in England and Wales each year.(2) The estimated prevalence of CML in 2003 in England and Wales was 2,660 patients.(2)

About Tasigna (nilotinib)

Nilotinib, a second generation TKI, is a potent and selective inhibitor of the Bcr-Abl protein, which is responsible for the proliferation of leukaemic white blood cells in Ph+ CML.(4,5) Nilotinib is indicated for the treatment of adults with chronic phase and accelerated phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.(5)

For nilotinib summary of product characteristics, please see: http://emc.medicines.org.uk/medicine/20827/SPC/ Tasigna%20200%20mg%20hard%20capsules

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About Glivec (imatinib)(7)

Imatinib is approved in the EU for the treatment of all phases of Ph+ CML. Imatinib is also indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) and the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.

Furthermore, imatinib is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy, adult patients with relapsed or refractory Ph+ ALL as monotherapy, adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR alpha rearrangement and the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

    For imatinib summary of product characteristics, please see:
    http://emc.medicines.org.uk/document.aspx?documentId=15014

    References

    (1) Saglio G, Kim DW, Issaragrisil S, Philipp le Coutre, et al.
        Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in
        Patients with Newly Diagnosed Chronic Myeloid Leukaemia in Chronic
        Phase: Results from the International Randomized Phase III ENESTnd
        Trial. American Society of Hematology 2009. Abstract number LBA-1

    (2) NICE Guidance on the use of imatinib for chronic myeloid leukaemia
        - Technology Appraisal 70. October 2003

    (3) Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian HM.
        The biology of chronic myeloid leukemia. N Engl J Med. 341:164-72,
        1999.

    (4) National Cancer Institute. General Information about Chronic
        Myelogenous Leukaemia (PDQ).
        http://www.cancer.gov/cancertopics/pdq/treatment/CML/patient/.
        Accessed March 2009.l 1: definition of PCR.

    (5) Tasigna (nilotinib) European Summary of Characteristics. Novartis AG.
        http://emc.medicines.org.uk/medicine/20827/SPC/Tasigna%20200%20mg%
        20hard%20capsules. 21/09/2009

        (Due to the length of this URL, it may be necessary to copy and paste
        this hyperlink into your Internet browser's URL address field. Remove
        the space if one exists.)

    (6) Hughes et al. Reduction of BCR-ABL Transcript Levels at 6, 12, and
        18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at
        72 Mo: An Analysis from the International Randomized Study of
        Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase
        Chronic Myeloid Leukemia (CML-CP). ASH. 2008. Abstract #334

    (7) Glivec (imatinib) European Summary of Characteristics. Novartis AG.
        http://emc.medicines.org.uk/document.aspx?documentId=15014.
        03/06/2009

SOURCE Novartis Oncology


'/>"/>
SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... DUBLIN, Ohio , Feb. 4, 2016 ... Pricing Program, or those already participating in the program, ... Guidance, often referred to as the , Mega-Guidance , ... the final guidance is published in September 2016. ... 340B Product and Service Marketing , summarizes the Mega-Guidance,s ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the ... Carman transitioned to chief of the Division of Plastic Surgery at what is now ... and began a second three-year term in January of 2016. , The original selection ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
Breaking Medicine News(10 mins):